SCHEMBL4295841

SCHEMBL4295841

N#Cc1cc(-c2nnn(Cc3ccccc3)c2CC2CCCCC2)ccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 9/20 0.59
ROCK2 O75116 4/20 0.38
PRKACA P17612 4/20 0.38
CDK2 P24941 4/20 0.38
PIM1 P11309 3/20 0.38
DAPK3 O43293 3/20 0.38
FLT3 P36888 3/20 0.38
CDK5 Q00535 3/20 0.38
DYRK1A Q13627 3/20 0.38
MAPK13 O15264 2/20 0.38
JAK2 O60674 2/20 0.38
PRKCG P05129 2/20 0.38
CDK1 P06493 2/20 0.38
MARK3 P27448 2/20 0.38
MAPK1 P28482 2/20 0.38
AKT1 P31749 2/20 0.38
AKT2 P31751 2/20 0.38
GSK3A P49840 2/20 0.38
MAPK12 P53778 2/20 0.38
CSNK2A1 P68400 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289379 0.99 CDC7 (0.58) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL4291352 0.84 CDC7 (0.58) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL4296221 0.84 CDC7 (0.53) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL3665335 0.81 ROCK2 (0.58) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL3637386 0.78 CDC7 (0.55) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL3666291 0.78 CDC7 (0.53) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL3667996 0.78 CDC7 (0.53) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL4289119 0.77 CDC7 (0.58) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL4295506 0.74 CDC7 (1.00) CDC7ROCK2PRKACACDK2PIM1
SCHEMBL3665208 0.73 CDC7 (0.58) CDC7ROCK2PRKACACDK2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885PRKACA 178/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885PRKACA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.